Four Arno to present 4 abstracts at San Diego conference
AR-12 is currently in development. The presentations will be Saturday at the San Diego conference and will consist of one podium presentation and three poster presentations, Arno Therapeutics said.
AR-12 has completed the first phase of clinical trials for patients with cancer, with additional preclinical information suggesting that the candidate could be used for other infections. Arno Therapeutics said that the candidate has received orphan drug designations in Europe to test its efficacy against tularemia and cryptococcosis.
Arno Therapeutics currently is evaluating interest in the possibility of developing an antiviral form of the candidate based around the AR-12 compound portfolio in order to provide a treatment option for viruses and pathogens that are of interest in biodefense circles. This stage is within an agreement between the company and the U.S. Army Medical Research Institute of Infectious Diseases.
The presentations will take place Saturday at the conference at the San Diego Convention Center.